[Skip to Navigation]
July 1982

Modulation of Experimental Autoimmune Uveitis With Cyclosporin A

Author Affiliations

From the Clinical Branch and the Laboratory of Vision Research (Drs Nussenblatt, Rodrigues, Salinas-Carmona, and Gery and Mr Cevario), National Eye Institute, National Institutes of Health, Bethesda, Md; and the University of Louisville (Dr Wacker).

Arch Ophthalmol. 1982;100(7):1146-1149. doi:10.1001/archopht.1982.01030040124022

• Cyclosporin A has been shown to be an effective inhibitor of T cell-mediated diseases. We show here that cyclosporin A was capable of totally preventing the clinical appearance of experimental autoimmune uveitis in Lewis rats, even when administered on an every-other-day schedule (10 mg/kg) or when begun seven days after immunization (40 mg/kg). At lower doses of the drug, a modulation of the disease was seen with evidence of a more chronic, granulomatous process. A long-lasting unresponsive state to the immunizing antigen was not uniformly induced with cyclosporin A if therapy was begun seven days after S antigen immunization. Because of cyclosporin A's effective control of this experimental model that is induced by an antigen to which certain patients with uveitis demonstrate cell-mediated immune responses, cyclosporin A may be an effective mode of therapy for T cell-mediated intraocular inflammatory disease.